News

Valneva announced the signing of a new $59 million contract with the U.S. government Department of Defense for the supply of its Japanese encephalitis...

Valneva confirmed its revenue and product sales guidance for 2018 and provided initial product sales guidance for 2019.

Phase 1 interim results showed an excellent immunogenicity profile after a single-shot vaccination and an acceptable safety profile, supporting...

Ares Genetics to start EUR 1.3 million TRIPLE-A development project co-funded by Vienna Business Agency, and initiates set-up of R&D and service...

Valneva announced that it intends to delist from the Vienna Stock Exchange (VSE) in order to focus on the best capital markets for life science...

The agreement grants Gilead exclusive rights to HOOKIPA’s TheraT® and VaxWave® investigational arenavirus-based immunization technologies for the...

Valneva announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its chikungunya vaccine candidate, VLA1553. ...

In January 2019, the new Managing Director of the Vienna BioCenter Core Facilities GmbH, Daniele Soroldoni, has started his work. Welcome!

The Vienna Biocenter Summer School provides a unique opportunity for approx. 28 undergraduate students to work side-by-side with leading researchers...

Strategic collaboration agreement with Sandoz to develop digital anti-infectives platform.

Valneva today announced the initiation of the Phase 2 Clinical Development for its leading, unique Lyme disease vaccine candidate VLA15.

The clinical trial will be conducted at approximately 35 centers worldwide and will include a total of 150 male and female patients.